Pfizer Inc. develops, manufactures, and sells healthcare products worldwide.
Outstanding track record established dividend payer.
Share Price & News
How has Pfizer's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PFE has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PFE underperformed the Austrian Pharmaceuticals industry which returned 14.4% over the past year.
Return vs Market: PFE underperformed the Austrian Market which returned -19.3% over the past year.
Price Volatility Vs. Market
How volatile is Pfizer's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Pfizer undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PFE (€30.6) is trading below our estimate of fair value (€73.12)
Significantly Below Fair Value: PFE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PFE is good value based on its PE Ratio (12x) compared to the Pharmaceuticals industry average (24.7x).
PE vs Market: PFE is poor value based on its PE Ratio (12x) compared to the Austrian market (11.2x).
Price to Earnings Growth Ratio
PEG Ratio: PFE is poor value based on its PEG Ratio (3.2x)
Price to Book Ratio
PB vs Industry: PFE is good value based on its PB Ratio (2.9x) compared to the XE Pharmaceuticals industry average (3.2x).
How is Pfizer forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PFE's forecast earnings growth (3.7% per year) is above the savings rate (0.5%).
Earnings vs Market: PFE's earnings (3.7% per year) are forecast to grow slower than the Austrian market (21.6% per year).
High Growth Earnings: PFE's earnings are forecast to grow, but not significantly.
Revenue vs Market: PFE's revenue (3.1% per year) is forecast to grow slower than the Austrian market (3.3% per year).
High Growth Revenue: PFE's revenue (3.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PFE's Return on Equity is forecast to be high in 3 years time (24.4%)
How has Pfizer performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PFE has high quality earnings.
Growing Profit Margin: PFE's current net profit margins (31.2%) are higher than last year (21.3%).
Past Earnings Growth Analysis
Earnings Trend: PFE's earnings have grown by 18.3% per year over the past 5 years.
Accelerating Growth: PFE's earnings growth over the past year (37.7%) exceeds its 5-year average (18.3% per year).
Earnings vs Industry: PFE earnings growth over the past year (37.7%) exceeded the Pharmaceuticals industry 7%.
Return on Equity
High ROE: PFE's Return on Equity (24.2%) is considered high.
How is Pfizer's financial position?
Financial Position Analysis
Short Term Liabilities: PFE's short term assets ($34.7B) exceed its short term liabilities ($33.9B).
Long Term Liabilities: PFE's short term assets ($34.7B) do not cover its long term liabilities ($67.1B).
Debt to Equity History and Analysis
Debt Level: PFE's debt to equity ratio (78%) is considered high.
Reducing Debt: PFE's debt to equity ratio has increased from 53.3% to 78% over the past 5 years.
Debt Coverage: PFE's debt is well covered by operating cash flow (27.5%).
Interest Coverage: PFE's interest payments on its debt are well covered by EBIT (12.6x coverage).
What is Pfizer current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: PFE's dividend (4.47%) is higher than the bottom 25% of dividend payers in the Austrian market (1.65%).
High Dividend: PFE's dividend (4.47%) is low compared to the top 25% of dividend payers in the Austrian market (4.94%).
Stability and Growth of Payments
Stable Dividend: PFE's dividends per share have been stable in the past 10 years.
Growing Dividend: PFE's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (51.3%), PFE's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: PFE's dividends in 3 years are forecast to be covered by earnings (53.8% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Albert Bourla (58yo)
Dr. Albert Bourla, DVM, Ph.D. serves as the Chief Executive Officer of Pfizer Inc. since January 1, 2019 and has been its Executive Director since February 23, 2018. Dr. Bourla was Chief Operating Officer ...
CEO Compensation Analysis
Compensation vs Market: Albert's total compensation ($USD17.93M) is above average for companies of similar size in the Austrian market ($USD4.02M).
Compensation vs Earnings: Albert's compensation has increased by more than 20% in the past year.
|Chairman of the Board & CEO||1.5yrs||US$17.93m||0.0038% $6.5m|
|Group President & Chief Business Officer||8.08yrs||US$8.96m||0.0076% $13.0m|
|CFO & EVP of Global Supply & Business Operations||12.83yrs||US$11.08m||0.0077% $13.0m|
|Chief Scientific Officer and President of Worldwide Research||1.5yrs||US$9.60m||no data|
|Senior VP||0.33yr||no data||0.00014% $237.6k|
|Executive VP and Chief Digital & Technology Officer||1.5yrs||no data||0.00078% $1.3m|
|Senior Vice President of Investor Relations||12.08yrs||no data||no data|
|Executive VP & General Counsel||6.58yrs||no data||0.0014% $2.4m|
|Executive VP and Chief Compliance||6.58yrs||no data||0.0013% $2.1m|
|Executive VP & Chief Development Officer||4.33yrs||no data||0.0022% $3.7m|
Experienced Management: PFE's management team is seasoned and experienced (5.5 years average tenure).
|Chairman of the Board & CEO||1.5yrs||US$17.93m||0.0038% $6.5m|
|Independent Director||23.42yrs||US$385.00k||no data|
|Lead Independent Director||2.25yrs||US$400.00k||no data|
|Independent Director||3.42yrs||US$350.00k||no data|
|Independent Director||12.83yrs||US$355.00k||0.000040% $67.9k|
|Independent Director||12.83yrs||US$380.00k||0.00018% $305.4k|
|Independent Director||6.08yrs||US$380.00k||0.000060% $101.8k|
|Member of Emerging Markets Advisory Board||no data||no data||no data|
|Independent Director||5.08yrs||US$365.00k||no data|
|Independent Director||8.58yrs||US$383.60k||no data|
Experienced Board: PFE's board of directors are considered experienced (6.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PFE insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Pfizer Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Pfizer Inc.
- Ticker: PFE
- Exchange: WBAG
- Founded: 1849
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$191.697b
- Listing Market Cap: US$169.690b
- Shares outstanding: 5.55b
- Website: https://www.pfizer.com
Number of Employees
- Pfizer Inc.
- 235 East 42nd Street
- New York
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PFE||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Jan 1968|
|PFE *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jan 1968|
|0Q1N||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jan 1968|
|PFE||OM (OMX Nordic Exchange Stockholm)||Yes||Common Stock||SE||SEK||Jan 1968|
|PFE||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 1968|
|PFE||XTRA (XETRA Trading Platform)||Yes||Common Stock||DE||EUR||Jan 1968|
|PFE||BVC (Bolsa de Valores de Colombia)||Yes||Common Stock||CO||COP||Jan 1968|
|PFES||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Stock||GB||SEK||Jan 1968|
|PFE||SNSE (Santiago Stock Exchange)||Yes||Common Stock||CL||USD||Jan 1968|
|PF-U||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||Jan 1968|
|PFE||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||Jan 1968|
|PFE||BVL (Bolsa de Valores de Lima)||Yes||Common Stock||PE||USD||Jan 1968|
|US_PFE_||KAS (Kazakhstan Stock Exchange)||Yes||Common Stock||KZ||KZT||Jan 1968|
|PFE||BASE (Buenos Aires Stock Exchange)||CEDEAR EACH 2 REP 1 ORD USD0.05||AR||ARS||Sep 2000|
|PFIZ34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR REPR 1 COM STK NPV||BR||BRL||May 2011|
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, such as cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; oncology, such as biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; licensing agreement with Akcea Therapeutics, Inc; strategic alliance with Verily Life Sciences LLC; collaboration agreements with Merck KGaA and Valneva SE; clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; material transfer and collaboration agreement with BioNTech SE to co-develop COVID-19 vaccine; clinical supply collaboration with Jiangsu Alphamab Biopharmaceuticals Co., Ltd; and research collaboration and license agreement with BioInvent International AB. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/07 21:15|
|End of Day Share Price||2020/07/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.